Immunochemoradiotherapy for patients with oral squamous cell carcinoma: Augmentation of OK-432-induced helper T cell 1 response by 5-FU and X-rays irradiation

Neoplasia (United States)

Volumn 15, Issue 7, 2013, Pages 805-814

  Tano, Tomoyuki ^a   Okamoto, Masato ^b   Kan, Shin ^c   Bando, Takashi ^d   Goda, Hiroyuki ^a   Nakashiro, Koh Ichi ^a   Shimodaira, Shigetaka ^e   Koido, Shigeo ^f   Homma, Sadamu ^f   Fujita, Tomonobu ^a   Sato, Mitsunobu ^d   Yamashita, Naomi ^g   Hamakawa, Hiroyuki ^a   Kawakami, Yutaka ^b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e SHINSHU UNIVERSITY HOSPITAL   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g MUSASHINO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 10; PICIBANIL; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHEMORADIOTHERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; X IRRADIATION;

EID: 84879620320     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13488     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ (2009). Cancer statistics. CA Cancer J Clin 59, 225-249.
2. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et al. (2003). Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349, 2091-2098.
3. Creaven PJ, Rustum YM, Petrelli NJ, and Gorbunova VA (1993). Clinical studies of the modulation of Ftorafur. In Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation. YM Rustum (Ed). Raven Press, New York, NY. pp. 253-262.
4. Yamamoto J, Toide K, Haruno A, Yoshimura Y, and Unemi N (1981). General pharmacological properties of UFT, a new type of anticancer agent consisting of 1-(2-tetrahydrofurayl)-5-fluorouracil (FT) and uracil. Drug Res 31, 1268-1278.
5. Okamoto H, Shoin S, Koshimura S, and Shimizu R (1967). Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 11, 323-336.
6. Kikkawa F, Kawai M, Oguchi H, Kojima M, Ishikawa H, Iwata M, Maeda O, Tomoda Y, Arii Y, and Kuzuya K (1993). Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma. Eur J Cancer 29, 1542-1546.
7. Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, and Sugimachi K (1994). Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 168, 36-40.
8. Sato M, Harada K, Yoshida H, Yura Y, Azuma M, Iga H, Bando T, Kawamata H, and Takegawa Y (1997). Therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: association of the therapeutic effect with differentiation and apoptosis in the cancer cells. Apoptosis 2, 227-238.
9. Okamoto M, Oshikawa T, Tano T, Ohe G, Furuichi S, Nishikawa H, Ahmed SU, Akashi S, Miyake K, Takeuchi O, et al. (2003). Involvement of Toll-like receptor 4 signaling in interferon-γ production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 95, 316-326.
10. Oshimi K, Kano S, Takaku F, and Okumura K (1980). Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst 65, 1265-1269.
11. Misaki T, Watanabe Y, Iida Y, Hidaka A, Kasagi K, Fukushima H, and Konishi J (1992). Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy. Cancer Immunol Immunother 35, 92-96.
12. Fujimoto T, Duda RB, Azilvasi A, Chen X, Mai M, and O'Donnell MA (1997). Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 158, 5619-5626.
13. Itoh T, Ueda Y, Okugawa K, Fujiwara H, Fuji N, Yamashita T, Fujiki H, Harada S, Yoshimura T, and Yamagishi H (2003). Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol Immunother 52, 207-214.
14. Nakahara S, Tsunoda T, Baba T, Asabe S, and Tahara H (2003). Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 63, 4112-4118.
15. Ahmed SU, Okamoto M, Oshikawa T, Tano T, Sasai A, Kan S, Hiroshima T, Ohue H, Moriya Y, Ryoma Y, et al. (2004). Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of Toll-like receptor 4. J Immunother 27, 432-441.
16. Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, et al. (2004). Expression of Toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cellbased immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 64, 5461-5470.
17. Okamoto M, Oshikawa T, Ohe G, Nishikawa H, Furuichi S, Tano T, Moriya Y, Saito M, and Sato M (2001). Severe impairment of anti-cancer effect of lipoteichoic acid-related molecule isolated from a penicillin-killed Streptococcus pyogenes in Toll-like receptor 4-deficient mice. Int Immunopharmacol 1, 1789-1795.
18. Oshikawa T, Okamoto M, Tano T, Sasai A, Kan S, Moriya Y, Ryoma Y, Saito M, Akira S, and Sato M (2006). Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent. J Immunother 29, 143-150.
19. Okamoto M, Oshikawa T, Tano T, Ahmed SU, Kan S, Sasai A, Akashi S, Miyake K, Moriya Y, Ryoma Y, et al. (2006). Mechanism of anticancer host re\sponse induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J Immunother 29, 78-86.
20. Rock FL, Hardiman G, Timans JC, Kastelein RA, and Bazan JF (1998). A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 95, 588-593.
21. Aderem A and Ulevitch RJ (2000). Toll-like receptors in the induction of the innate immune response. Nature 406, 782-787.
22. Sobin H, Gospodarowicz MK, and Wittekind C (Eds.) (2009). International Union against Cancer (UICC): TNM Classification of Malignant Tumors (7th ed). Wiley-Blackwell, West Sussex, United Kingdom.
23. Arakawa S, Hatano Y, and Katagiri K (2004). Differential expression of mRNA for Th1 and Th2 cytokine-associated transcription factors and suppressors of cytokine signalling in peripheral blood mononuclear cells of patients with atopic dermatitis. Clin Exp Immunol 135, 505-510.
24. -T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172, 5149-5153.
25. Ding Y, Chen D, Tarcsafalvi A, Su R, Qin L, and Bromberg JS (2003). Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune response. J Immunol 170, 1383-1391.
26. Nakashiro K, Kawamata H, Hino S, Uchida D, Miwa Y, Hamano H, Omotehara F, Yoshida H, and Sato M (1998). Down-regulation of TSC-22 (transforming growth factor β-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. Cancer Res 86, 549-555.
27. Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H, and Nishimura T (2010). Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res 70, 2697-2706.
28. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56, 641-648.
29. Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY, Sakaguchi S, and Kang CY (2007). A combination of chemoimmunotherapies can efficiently break selftolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 67, 7477-7486.
30. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, and Coffman RL (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136, 2348-2357.
31. Gorelik L, Prokhorova A, and Mokyr MB (1994). Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 139, 117-126. http://www.ncbi.nlm.nih.gov/pubmed?term=Gorelik%201994%20Th1.
32. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194, 823-832.
33. Fujino A, Moriya Y, Morikawa Y, Hoshino K, Watanabe T, Shimojima N, and Kitajima M (2003). A role of cytokines in OK-432 injection therapy for cystic lymphangioma: an approach to the mechanism. J Pediatr Surg 38, 1806-1809.
34. Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, and Yoshimura A (2011). Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol 31, 980-985.
35. Seki Y, Inoue H, Nagata N, Hayashi K, Fukuyama S, Matsumoto K, Komine O, Hamano S, Himeno K, Inagaki-Ohara K, et al. (2003). SOCS-3 regulates onset and maintenance of TH2-mediated allergic responses. Nat Med 29, 1047-1054.
36. Okamoto M, Kasetani H, Kaji R, Goda H, Ohe G, Yoshida H, and Sato M (1998). cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol Immunother 47, 233-241.
37. Okamoto M, Ohe G, Oshikawa T, Nishikawa H, Furuichi S, Yoshida H, and Sato M (2000). Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients. Anticancer Drugs 11, 165-173.
38. Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, et al. (2012). Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 41, 195-205.
39. Heine A, Held SA, Bringmann A, Holderried TA, and Brossart P (2011). Immunomodulatory effects of anti-angiogenic drugs 25, 899-905.
40. Tano T, Okamoto M, Kan S, Nakashiro K, Shimodaira S, Koido S, Homma S, Sato M, Fujita T, Kawakami Y, et al. (2013). Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma. Neoplasia 15, 305-314.
41. Yoshimura A, Miri H, Ohishi M, Aki D, and Hanada T (2004). Regulation of TLR signaling and inflammation by SOCS family proteins. J Leukoc Biol 75, 422-427.